Alan D. D'Andrea , MD

	Co-Director, Gene Therapy Center Office Phone: 617-632-2112 Appointment Line: 1-888-PEDI-ONC (733-4662) Fax: 617-632-5757 Email this provider NPI: 1174599930

Co-Director, Gene Therapy Center

Office Phone: 617-632-2112

Appointment Line: 1-888-PEDI-ONC (733-4662)

Fax: 617-632-5757

NPI: 1174599930

Hematology

cancer susceptibility

Fanconi anemia

gene therapy

genetic risk

hematology

Alvan T. and Viola D. Fuller American Cancer Society Professor of Radiation Oncology, Harvard Medical School

Pediatrics

Harvard Medical School, Boston, MA (1983)

Children's Hospital of Philadelphia, Philadelphia, PA (06/83 to 06/84)

Children's Hospital of Philadelphia, Philadelphia, PA (06/84 to 06/86)

Children's Hospital Boston/Dana Farber Cancer Institute, Boston, MA (06/86 to 06/87)

Fanconi Anemia, DNA Repair

Pathophysiology of Fanconi anemia and functions of the eight known genes and gene products that cause Fanconi anemia. Linkage to BRCA1, BRCA2, NBS1 and ataxia telangiectasia DNA repair mechanisms. (Nat Genet 17:487, 1997; Proc Natl Acad Sci USA 95:13085, 1998; Blood 96:3224, 2000; Molec Cell 7:241 and 7:249, 2001; Nat Med 7:1259, 2001; Cell 109:459, 2002; Science, 297:606, 2002; Nat Cell Biol 4:913, 2002; Dev Cell 5: 903, 2003; Genes Dev 18:1958, 2004; Proc Natl Acad Sci USA 102:1110,2005)
Some tumors increase their mutagenic rate by somatic mutations that disrupt the Fanconi pathway (Nat Med 9:568, 2003), but may revert and become chemotherapy resistant (Cancer Res 15:2688, 2003)
Deubiquinating enzymes regulate Fanconi pathway (Mol Cell 17:331, 2005; Nat Cell Biol 8:339,2006

Research site for Alan D'Andrea, MD